Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
Fish and Richardson
Chubb
Accenture
Julphar
Fuji
Harvard Business School
Novartis
Queensland Health

Generated: August 18, 2017

DrugPatentWatch Database Preview

Glaxo Grp Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXO GRP LTD, and what generic alternatives to GLAXO GRP LTD drugs are available?

GLAXO GRP LTD has eight approved drugs.

There are thirty US patents protecting GLAXO GRP LTD drugs.

There are five hundred and one patent family members on GLAXO GRP LTD drugs in fifty-seven countries.

Summary for Applicant: Glaxo Grp Ltd

Patents:30
Tradenames:13
Ingredients:4
NDAs:8
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-003Jun 8, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-002May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
ADVAIR HFA
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-001Jun 8, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Glaxo Grp Ltd
ZANTAC 300
ranitidine hydrochloride
TABLET;ORAL018703-002Dec 9, 1985ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Glaxo Grp Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd
ADVAIR DISKUS 500/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-003Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 100/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-001Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp Ltd
ZANTAC 300
ranitidine hydrochloride
TABLET;ORAL018703-002Dec 9, 1985► Subscribe► Subscribe
Glaxo Grp Ltd
FLOVENT DISKUS 100
fluticasone propionate
POWDER;INHALATION020833-002Sep 29, 2000► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 250/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-002Aug 24, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GLAXO GRP LTD drugs

Drugname Dosage Strength Tradename Submissiondate
ranitidine hydrochloride
Tablets150 mg
ZANTAC 150
10/30/2007

Non-Orange Book Patents for Glaxo Grp Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,378,519 Inhalation device► Subscribe
8,198,483Phenethanolamine derivatives for treatment of respiratory diseases► Subscribe
7,592,329Crystalline complexes of fluticasone-2-furoate► Subscribe
7,144,845Compounds useful in the manufacture of an anti-inflammatory androstane derivative► Subscribe
6,858,593 Anti-inflammatory androstane derivative compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Glaxo Grp Ltd Drugs

Country Document Number Estimated Expiration
United Kingdom0403394► Subscribe
Sweden512934► Subscribe
World Intellectual Property Organization (WIPO)03066656► Subscribe
Australia2003281751► Subscribe
Spain2031763► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Glaxo Grp Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008 00022Denmark► Subscribe
1425001/02Switzerland► SubscribePRODUCT NAME: VILANTEROL UND FLUTICASON FUROAT; REGISTRATION NO/DATE: SWISSMEDIC 62969 09.01.2014
C011/2008Ireland► SubscribeSPC011/2008: 20081105, EXPIRES: 20230110
2008000029Germany► SubscribePRODUCT NAME: FLUTICASONFUROAT UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/07/434/001-003 20080111
C0014France► SubscribePRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Colorcon
US Army
Mallinckrodt
QuintilesIMS
McKinsey
Johnson and Johnson
Fish and Richardson
Covington
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot